Our Story
Luvantas®is the North American subsidiary of Medytox Inc., a globally recognized biopharmaceutical company with a rich history of innovation in medical aesthetics.
Established in 2000 and headquartered in Seoul, South Korea, Medytox is the original Korean manufacturer and the world’s first company to introduce a liquid ready-to-use formulation of Botulinum toxin type A. Medytox products are marketed in 60 countries, offering a comprehensive portfolio of medical aesthetic solutions including dermal fillers and topical skincare in addition to a wide range of Botulinum toxin products in international markets outside the United States. Medytox is publicly traded on the Korean KOSDAQ exchange (086900.KQ).
World-class research facilities and state-of-the-art manufacturing plants demonstrate the Medytox commitment to innovation, scientific excellence, and product quality.
Luvantas is seeking approval for the upcoming introduction of NivobotulinumtoxinA to the United States and Canada. More information on this state-of-the-art formulation of Botulinum toxin will be provided in the future once regulatory approvals are obtained. Luvantas intends to seek approval to introduce other innovative medical aesthetic offerings from Medytox, as well as partner with emerging companies and inventors to support the commercialization of unique medical aesthetic solutions.
Medytox Plant II is located in Osong (South Korea’s Biotechnology Hub) and is designed to meet the cGMP standards of the U.S. FDA and the GMP standards of the European Medicines Authority. It will serve as the production facility for NivobotulinumtoxinA. This modern manufacturing facility, built with Global expansion in mind, produced the NivobotulinumtoxinA clinical product for Phase 3 studies that were conducted in the United States, Canada and the European Union.